CIMAvax-EGF is a Cuban vaccine for advanced non-small cell lung cancer, given after chemotherapy so the body blocks a growth signal the tumour uses. Cuba registered it in 2008. In its phase III trial the survival gain was not significant by the standard test, but was by a weighted test and among patients given at least four doses. It is not approved in the United States or the European Union.
CIMAvax-EGF is made at the Centro de Inmunología Molecular in Havana, which holds its registration. It is recombinant human epidermal growth factor chemically conjugated to the recombinant carrier protein rP64K and emulsified with the adjuvant Montanide ISA 51 VG; the vaccine is intended to induce antibodies against the patient's own EGF that block its binding to the EGF receptor. Cuba's regulator CECMED lists it under registration number B-08-063-L03, entered on 12 June 2008, for patients with advanced (stage IIIB or IV) non-small cell lung cancer.
In the Cuban phase III trial, 405 patients with stage IIIB or IV disease were randomised four to six weeks after first-line chemotherapy to the vaccine or to best supportive care. Median survival was 10.83 months with the vaccine and 8.86 months without (hazard ratio 0.82, P = 0.100 by the standard log-rank test; P = 0.04 by a weighted log-rank test applied after the hazards proved non-proportional). Among patients who received at least four doses it was 12.43 against 9.43 months (hazard ratio 0.77, P = 0.036), and 14.66 months in vaccinated patients with a high EGF concentration at baseline. The trial compared the vaccine with supportive care, not with a placebo or with the maintenance and immunotherapy treatments now standard elsewhere. A phase 1/2 trial sponsored by Roswell Park in the United States combines it with nivolumab or pembrolizumab (NCT02955290).
Makes the body produce antibodies against its own epidermal growth factor (EGF), lowering EGF in the blood so that less of it reaches the EGF receptor on tumour cells. It does not target the tumour cell directly.
1.CIMAvax-EGF slips into a pocket on its target.
| Where | Who pays | Help with the cost | |
|---|---|---|---|
🇨🇺 Cuba Discussed on its page | Not recorded | - | - |
Approval is the regulator's decision for any cancer indication, with the year of the first; it is not a promise that a hospital stocks the drug or that your indication is covered. Not recorded for United States, European Union, United Kingdom, Japan, China, Australia, India: a gap in our research, not a refusal. Compare products across regions.
CECMED registration B-08-063-L03 entered for advanced non-small cell lung cancer (date of inscription in the summary of product characteristics) source
| Region | Year | Indication |
|---|---|---|
| Cuba (CECMED) | 2008 | Advanced (stage IIIB or IV) non-small cell lung cancer · Registration number B-08-063-L03, entered 12 June 2008; holder Centro de Inmunología Molecular. CECMED summary of product characteristics: "CIMAvax®-EGF está indicado en pacientes con cáncer de pulmón de células no pequeñas, en estadios avanzados (IIIb / IV)." https://www.cecmed.cu/registro/rcp/biologicos/cimavaxr-egf-conjugado-quimico-factor-crecimiento-epidermico-humano |
| Adverse event |
|---|
| Injection-site reactions; flushing, chills, tremor, headache, nausea, vomiting, fever |
The CECMED summary describes most adverse events as mild or moderate across more than 1,000 patients in 13 trials, and says severe systemic reactions can occur and respond to antihistamines, antipyretics and analgesics.. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"CIMAvax-EGF" OR ABSTRACT:"CIMAvax-EGF" OR TITLE:"CIMAvax" OR ABSTRACT:"CIMAvax" OR TITLE:"EGF vaccine" OR ABSTRACT:"EGF vaccine" OR TITLE:"rhEGF-rP64K conjugate vaccine" OR ABSTRACT:"rhEGF-rP64K conjugate vaccine") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CIMAvax-EGF, not a curated reading list.
Shares Center for State Control of Medicines, Equipment and Medical Devices (CECMED), CIMAB, Non-small-cell lung cancer and the tags cuba, cancer-vaccine.
Shares Center for State Control of Medicines, Equipment and Medical Devices (CECMED), CIMAvax-EGF as switch maintenance in advanced non-small cell lung cancer: the Cuban phase III trial.
Shares CIMAB, Non-small-cell lung cancer.
Shares Center for State Control of Medicines, Equipment and Medical Devices (CECMED), Non-small-cell lung cancer.
Shares CIMAvax-EGF as switch maintenance in advanced non-small cell lung cancer: the Cuban phase III trial, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/